Chemists from ETH Zurich have found a way to produce poorly soluble proteins by caging a uniquely reactive boron compound. This method opens up new possibilities for the synthesis of tailored protein ...

The breakthrough could simplify the production of complex proteins used in cancer immunotherapy and other advanced medicines ...

Boron chemistry, particularly the study of metallacarboranes, has emerged as a dynamic field with significant implications for modern medicinal applications. These compounds, characterised by robust ...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron ...

Epetraborole-treated patients demonstrated clinical improvements in QOL-B and a post-hoc analysis of MACrO2 with nominal statistical significance when evaluated as continuous measures First drug ...

Boron agents termed GluBs, developed by Science Tokyo researchers, have overcome a key limitation in cancer therapy by entering tumor cells through a pathway that standard drugs cannot use. The GluBs ...

Boron cluster chemistry occupies a unique niche in modern chemical science, bridging fundamental inorganic chemistry with practical materials applications. Central to this field is the study of ...

EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung disease ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has ...

Colleagues sometimes called M. Frederick Hawthorne “Mr. Boron,” and it was a nickname he embraced. He often said that boron was his element, but then he’d quickly clarify that it wasn’t that he owned ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced ...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron ...